GH/IGF-1 Axis as a Gerotherapeutic Target
Sofiya Milman
TL;DR
This paper explores how reducing GH/IGF-1 signaling may promote healthy aging and protect against age-related diseases in humans.
Contribution
The paper synthesizes epidemiological and genetic evidence to propose GH/IGF-1 as a potential gerotherapeutic target.
Findings
Attenuated GH/IGF-1 signaling is linked to healthy aging and reduced risk of age-related diseases.
Preclinical trials are exploring therapeutics that reduce GH/IGF-1 signaling to delay aging.
Evidence comes from general populations and exceptional longevity cohorts.
Abstract
While growth hormone/ insulin like growth factor-1 (GH/IGF-1) is a well-documented modulator of aging and longevity in model organisms, its role in human aging is less established. Growing epidemiologic and genetic evidence from general population and exceptional longevity cohorts is pointing to attenuated GH/IGF-1 signaling as a mediator of healthy aging and protection against age-related diseases, including cancer, diabetes, dementia, and cardiovascular disease. This evidence has led to preclinical trials of newly developed and repurposed therapeutics that diminish GH/IGF-1 signaling, with the potential to delay aging and age-related diseases in people.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGrowth Hormone and Insulin-like Growth Factors · GDF15 and Related Biomarkers · Glycogen Storage Diseases and Myoclonus